Breaking News

ICON Appoints Analytics and Consulting VP

September 3, 2014

Spector brings 25 years of experience

Dr. Ira Spector has been appointed executive vice president, Analytics and Consulting, ICON plc. Dr. Spector will lead ICON’s global consulting and drug development services and will be responsible for business process improvement and analytics capabilities.
Dr. Spector has more than 25 years of experience in managing global drug and medical device development programs. He joins the company from Allergan Pharmaceuticals, where he was senior vice president of Global Development Operations, responsible for 11 global research centers, which contributed to approvals in more than 51 countries.
Dr. Spector previously spent 17 years at Wyeth Research, most recently as vice president, Global Development Operations and vice chief of Development, responsible for global clinical trial management.
Dr. Steve Cutler, chief operating officer at ICON, said, “I would like to welcome Dr. Spector to the ICON team. His extensive experience in managing some of the world’s largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers’ drug and device programs.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important